↑ 疾患リストへ ← 戻る

 269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 [臨床試験数:18,薬物数:22(DrugBank:11),標的遺伝子数:12,標的パスウェイ数:18] 

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03971643May 16, 201911 November 2019Exploratory Study of IFX-1 in Subjects With Pyoderma GangrenosumOpen Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma GangrenosumPyoderma GangrenosumDrug: IFX-1InflaRx GmbHInnovaderm Research Inc.Recruiting18 YearsN/AAll12Phase 2United States;Canada
2NCT03311464October 27, 201730 September 2019A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanA Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in JapanPyoderma GangrenosumDrug: adalimumabAbbVieNot recruiting18 YearsN/AAll22Phase 3Japan
3NCT03072953June 7, 20173 June 2019Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumA Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma GangrenosumPyoderma GangrenosumDrug: APD334Arena PharmaceuticalsNot recruiting18 Years80 YearsAll2Phase 2Australia;New Zealand
4NCT03137160May 4, 201718 December 2018An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumAn Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumBiological: IxekizumabOhio State UniversityEli Lilly and CompanyNot recruiting18 YearsN/AAll5Phase 2United States
5NCT02733094April 201611 June 2018Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumSingle-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: SecukinumabTechnische Universität MünchenNovartisRecruiting18 Years75 YearsAll5Phase 1/Phase 2Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-000762-65-DE09/07/20155 June 2017Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuSingle-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosumPyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.
MedDRA version: 20.0 Level: PT Classification code 10037635 Term: Pyoderma gangrenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Cosentyx®
Product Name: Cosentyx
Product Code: EU/1/14/980/002; EU/1/14/980/003
Pharmaceutical Form: Solution and suspension for suspension for injection in pre-filled syringe
Technische Universität München, School of Medicine, represented by DeanAuthorisedFemale: yes
Male: yes
7Phase 2;Phase 3Germany
7NCT02366260February 20152 March 2015An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: Gevokizumab;Drug: PlaceboMedDerm AssociatesXOMA (US) LLCRecruiting18 YearsN/ABoth5Phase 3United States
8NCT02326740December 20149 May 2016An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNot recruiting18 YearsN/ABoth9Phase 3United States;Australia;Canada
9NCT02315417November 20149 May 2016An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNot recruiting18 YearsN/ABoth16Phase 3United States
10NCT02318914November 20149 May 2016A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumA 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNot recruiting18 YearsN/ABoth15Phase 3United States;Australia;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01965613January 201416 December 2017A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumA Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumPyoderma GangrenosumBiological: XilonixXBiotech, Inc.Not recruiting18 YearsN/AAll10Phase 2United States
12NCT01882504May 201315 February 2016Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumAn Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNot recruiting18 YearsN/ABoth8Phase 2United States
13EUCTR2011-002920-41-DE04/01/201210 March 2014Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosumOpen-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-TrialPatients with a clinical diagnosis of Pyoderma gangrenosum
MedDRA version: 14.1 Level: LLT Classification code 10037634 Term: Pyoderma gangenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: Stelara
Product Name: Ustekinumab
Pharmaceutical Form: Solution for injection
CAS Number: 815610-63-0
Other descriptive name: USTEKINUMAB
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 45-90
University Hospital TübingenNot RecruitingFemale: yes
Male: yes
Germany
14NCT01302795February 201110 October 2016Canakinumab for Pyoderma GangrenosumA Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: CanakinumabUniversity of ZurichNot recruiting18 Years99 YearsBoth5Phase 2Switzerland
15EUCTR2008-008291-14-GB14/05/20093 September 2012Study of treatments in Pyoderma Gangrenosum patients - STOP GAPStudy of treatments in Pyoderma Gangrenosum patients - STOP GAPpyoderma gangrenosum
MedDRA version: 14.0 Level: LLT Classification code 10037634 Term: Pyoderma gangenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.0 Level: PT Classification code 10037635 Term: Pyoderma gangrenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Trade Name: Neoral soft gelatin capsules
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: CICLOSPORIN
CAS Number: 59865133
Trade Name: Neoral Oral Solution
Pharmaceutical Form: Oral solution
INN or Proposed INN: CICLOSPORIN
CAS Number: 59865133
Product Name: Prednisolone
Pharmaceutical Form: Tablet
INN or Proposed INN: PREDNISOLONE
CAS Number: 50248
Product Name: Prednisolone
Pharmaceutical Form: Soluble tablet
INN or Proposed INN: PREDNISOLONE
CAS Number: 50248
Product Name: Prednisolone
Pharmaceutical Form: Coated tablet
INN or Proposed INN: PREDNISOLONE
CAS Number: 50248
Nottingham University Hospitals NHS TrustAuthorisedFemale: yes
Male: yes
United Kingdom;Ireland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00730717May 200919 February 2015Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumMulti Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: HumiraWright State UniversityStanford University;Wake Forest School of MedicineNot recruiting18 YearsN/ABoth20Phase 2United States
17NCT00791557October 200819 October 2017Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseAn Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma GangrenosumPyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel DiseaseDrug: InfliximabUniversity Hospitals Cleveland Medical CenterCentocor, Inc.Not recruiting18 Years75 YearsAll2N/AUnited States
18NCT00690846July 200720 August 2018Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumA Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)Pyoderma GangrenosumDrug: adalimumabWake Forest University Health SciencesNot recruiting18 YearsN/AAll0Phase 2United States

先頭へ